J R Graff

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. doi request reprint Targeting the eukaryotic translation initiation factor 4E for cancer therapy
    Jeremy R Graff
    Cancer Growth and Translational Genetics, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Cancer Res 68:631-4. 2008
  2. ncbi request reprint The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts
    Jeremy R Graff
    Lilly Research Labs, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Cancer Res 65:7462-9. 2005
  3. pmc Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity
    Jeremy R Graff
    Lilly Research Labs, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Clin Invest 117:2638-48. 2007
  4. doi request reprint Modulation of 4E-BP1 function as a critical determinant of enzastaurin-induced apoptosis
    Chad A Dumstorf
    Lilly Research Labs, Eli Lilly and Company, Indianapolis, Indiana 46285
    Mol Cancer Ther 9:3158-63. 2010
  5. ncbi request reprint Emerging targets in the AKT pathway for treatment of androgen-independent prostatic adenocarcinoma
    Jeremy R Graff
    Cancer Division, Lilly Research Labs, Eli Lilly and Company, Lilly Corporate Centre, DC 0546, Indianapolis, IN 46285, USA
    Expert Opin Ther Targets 6:103-13. 2002
  6. ncbi request reprint Integrin-linked kinase expression increases with prostate tumor grade
    J R Graff
    Cancer Division, Lilly Research Labs, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Clin Cancer Res 7:1987-91. 2001
  7. ncbi request reprint Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression
    J R Graff
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Biol Chem 275:24500-5. 2000
  8. ncbi request reprint Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression
    J R Graff
    Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231, USA
    J Biol Chem 275:2727-32. 2000
  9. doi request reprint eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival
    Jeremy R Graff
    Lilly Research Labs, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Cancer Res 69:3866-73. 2009
  10. ncbi request reprint Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade
    J R Graff
    Lilly Research Labs, Cancer Research Division, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Clin Cancer Res 7:3857-61. 2001

Collaborators

Detail Information

Publications21

  1. doi request reprint Targeting the eukaryotic translation initiation factor 4E for cancer therapy
    Jeremy R Graff
    Cancer Growth and Translational Genetics, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Cancer Res 68:631-4. 2008
    ..These studies illustrate the increased susceptibility of tumor tissues to eIF4E inhibition and support the notion that the enhanced eIF4E function common to many tumor types may represent an Achilles' heel for cancer...
  2. ncbi request reprint The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts
    Jeremy R Graff
    Lilly Research Labs, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Cancer Res 65:7462-9. 2005
    ....
  3. pmc Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity
    Jeremy R Graff
    Lilly Research Labs, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Clin Invest 117:2638-48. 2007
    ..These data have prompted eIF4E-specific ASO clinical trials for the treatment of human cancers...
  4. doi request reprint Modulation of 4E-BP1 function as a critical determinant of enzastaurin-induced apoptosis
    Chad A Dumstorf
    Lilly Research Labs, Eli Lilly and Company, Indianapolis, Indiana 46285
    Mol Cancer Ther 9:3158-63. 2010
    ..These data highlight the importance of modulating 4E-BP1 function, and eIF4F complex levels, in the direct antitumor effect of enzastaurin and suggest that 4E-BP1 function may serve as a promising determinant of enzastaurin activity...
  5. ncbi request reprint Emerging targets in the AKT pathway for treatment of androgen-independent prostatic adenocarcinoma
    Jeremy R Graff
    Cancer Division, Lilly Research Labs, Eli Lilly and Company, Lilly Corporate Centre, DC 0546, Indianapolis, IN 46285, USA
    Expert Opin Ther Targets 6:103-13. 2002
    ....
  6. ncbi request reprint Integrin-linked kinase expression increases with prostate tumor grade
    J R Graff
    Cancer Division, Lilly Research Labs, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Clin Cancer Res 7:1987-91. 2001
    ..Furthermore, ILK expression increases with androgen-independent progression of human CaP cell lines, suggesting that increased ILK expression may be associated with CaP progression...
  7. ncbi request reprint Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression
    J R Graff
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Biol Chem 275:24500-5. 2000
    ....
  8. ncbi request reprint Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression
    J R Graff
    Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231, USA
    J Biol Chem 275:2727-32. 2000
    ....
  9. doi request reprint eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival
    Jeremy R Graff
    Lilly Research Labs, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Cancer Res 69:3866-73. 2009
    ..Collectively, these data implicate eIF4E activation in prostate cancer and suggest that targeting eIF4E may be attractive for prostate cancer therapy...
  10. ncbi request reprint Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade
    J R Graff
    Lilly Research Labs, Cancer Research Division, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Clin Cancer Res 7:3857-61. 2001
    ..015). CONCLUSIONS: These data show that sPLA2-IIa expression increases with progression to androgen-independence and is highest in the most poorly-differentiated, highest-grade primary human CaP samples...
  11. ncbi request reprint AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon
    M J Zinda
    Cancer Research Division, Lilly Research Labs, Eli Lilly and Company, Lilly Corporate Center DC 0546, Indianapolis, IN 46285, USA
    Clin Cancer Res 7:2475-9. 2001
    ....
  12. pmc Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands
    J G Herman
    Oncology Center, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Proc Natl Acad Sci U S A 93:9821-6. 1996
    ....
  13. ncbi request reprint The selective estrogen receptor modulator trioxifene (LY133314) inhibits metastasis and extends survival in the PAIII rat prostatic carcinoma model
    Blake Lee Neubauer
    Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Cancer Res 63:6056-62. 2003
    ..Our data support the contention that trioxifene represents a SERM with potential antimetastatic efficacy for the treatment of androgen-independent, metastatic PCa...
  14. ncbi request reprint Expression levels of protein kinase C-alpha in non-small-cell lung cancer
    Michael Lahn
    Oncology Product Development, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Clin Lung Cancer 6:184-9. 2004
    ..We found that PKC-alpha is highly expressed in < or = 20% of patients with NSCLC. We also found that PKC-alpha was preferentially expressed in adenocarcinoma compared with squamous cell carcinoma of the lung...
  15. pmc Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression
    L M McGregor
    Oncology Center, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Proc Natl Acad Sci U S A 96:4540-5. 1999
    ..These results suggest that trk family receptor genes participate in MTC development and progression, and, in particular, that trkB may limit MTC tumor growth by inhibition of angiogenesis...
  16. ncbi request reprint Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs
    Jeremy R Graff
    Lilly Research Labs, Cancer Research Division, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Clin Exp Metastasis 20:265-73. 2003
    ....
  17. ncbi request reprint The progression of LNCaP human prostate cancer cells to androgen independence involves decreased FOXO3a expression and reduced p27KIP1 promoter transactivation
    Rebecca L Lynch
    Lilly Research Labs, Cancer Division, Eli Lilly and Company, Lilly Corporate Center, Drop Code 0546, Indianapolis, IN 46285, USA
    Mol Cancer Res 3:163-9. 2005
    ..To the extent that this model reflects human disease, these data suggest that FOXO function may be compromised with androgen-independent progression of human prostate cancer...
  18. ncbi request reprint Targeting the eIF4F translation initiation complex for cancer therapy
    Bruce W Konicek
    Lilly Research Laboratories, Cancer Growth and Translational Genetics, Eli Lilly and Company, Indianapolis, Indiana46285, USA
    Cell Cycle 7:2466-71. 2008
    ..These studies have demonstrated the attractiveness and plausibility of targeting eIF4E and the eIF4F translation initiation complex for cancer therapy and have prompted the advance of the first eIF4E-specific therapy to the clinic...
  19. pmc Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma
    Jiazhong Jiang
    Department of Pathology, Division of Biostatistics, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Am J Pathol 160:667-71. 2002
    ..Our data are consistent with the contention that group IIA sPLA2 expression is elevated in neoplastic prostatic tissue and support the hypothesis that dysregulation of sPLA2 may play a role in prostatic carcinogenesis...
  20. ncbi request reprint Pak-1 expression increases with progression of colorectal carcinomas to metastasis
    Julia H Carter
    Wood Hudson Cancer Research Laboratory, Newport, Kentucky 41071, USA
    Clin Cancer Res 10:3448-56. 2004
    ..Because Pak-1 plays a central role in regulating cell motility and invasiveness, we sought to determine whether Pak-1 may be involved in the malignant progression of colorectal carcinoma...
  21. ncbi request reprint eIF-4E expression and its role in malignancies and metastases
    Arrigo De Benedetti
    Department of Biochemistry and Molecular Biology, Louisiana State University Medical Center, Shreveport, 1501 Kings Highway, PO Box 33932, Shreveport, LA 71130, USA
    Oncogene 23:3189-99. 2004
    ....